Potent non-urea inhibitors of soluble epoxide hydrolase

Abstract

The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.

What is claimed is: 
     
         1 . A compound of Formula 1: 
       
         
           
           
               
               
           
         
         wherein R 1  is independently selected for each occurrence from the group consisting of Phosphorus, substituted or unsubstituted benzothiazol, substituted or unsubstituted pyridyl, substituted or unsubstituted naphthyl, substituted or unsubstituted phenyl, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkalkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic, —C(O)R 3  and —S(O) 2 R 3 ; 
         wherein R 3  is independently selected for each occurrence from the groups consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted arylalkyl; substituted or unsubstituted heteroaryl; substituted or unsubstituted heterocyclic, substituted or unsubstituted naphthyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted benzothienyl, substituted or unsubstituted pyridyl, substituted or unsubstituted indol, substituted or unsubstituted isoquinolyl, substituted or unsubstituted quinolyl, and substituted or unsubstituted benzothiazol; 
         wherein R 2  is independently selected for each occurrence from the group consisting of Phosphorus, substituted or unsubstituted benzothiazol, substituted or unsubstituted pyridyl, substituted or unsubstituted naphthyl, substituted or unsubstituted phenyl, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkalkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic, —C(O)R 3  and —S(O) 2 R 3 ; 
         wherein R 3  is independently selected for each occurrence from the groups consisting of substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted arylalkyl; substituted or unsubstituted heteroaryl; substituted or unsubstituted heterocyclic, substituted or unsubstituted naphthyl, substituted or unsubstituted thienyl, substituted or unsubstituted benzothienyl, substituted or unsubstituted pyridyl, substituted or unsubstituted indol, substituted or unsubstituted isoquinolyl, substituted or unsubstituted quinolyl, and substituted or unsubstituted benzothiazol; 
         and further wherein, when R 2  is 
       
       
         
           
           
               
               
           
         
       
       and R 1  is a substituted phenyl, wherein the substituent is an unsubstituted alkyl, the alkyl is at least a C 3  alkyl; 
       and pharmaceutically acceptable salts and prodrugs thereof. 
     
     
         2 . The compound of  claim 1 , wherein R 1  is selected from the group consisting of a substituted aryl having one or more substituent which is a halogen. 
     
     
         3 . The compound of  claim 2 , wherein the halogen is selected from the group consisting of fluorine or chlorine. 
     
     
         4 . The compound of  claim 1 , wherein R 2  is —S(O) 2 R 3 , and wherein R 3  is selected from the group consisting of a substituted aryl having one or more substituent and an unsubstituted aryl. 
     
     
         5 . The compound of  claim 4 , wherein R 3  is a substituted aryl and the one or more substituent is selected from the group consisting of a hydrophobic alkyl group and a halide. 
     
     
         6 . The compound of  claim 4 , wherein R 3  is a substituted aryl having one or more substituent, and wherein at least one of the one or more substituents is in the ortho position. 
     
     
         7 . The compound of  claim 6 , wherein the one or more substituents in the ortho position is selected from the group consisting of a bromide, fluoride and methyl. 
     
     
         8 . The compound of  claim 1 , wherein R 1  is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         9 . The compound of  claim 1 , wherein R 2  is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         10 . The compound of  claim 1 , wherein R′ is independently selected for each occurrence from the group consisting of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         11 . The compound of  claim 1 , wherein R 2  is independently selected for each occurrence from the group consisting of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         12 . The compound of  claim 1 , wherein the compound is formulated as a pharmaceutical formulation.